TD Cowen on Oruka Therapeutics (ORKA): '39-49% Or Higher PASI 100 Should Unlock Multi-Billion Sales'
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented: "ORKA-001 Preview: 39-49 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
